Navigation Links
Prostate cancer spreads to bones by overtaking the home of blood stem cells
Date:3/23/2011

ANN ARBOR, Mich.---Like bad neighbors who decide to go wreck another community, prostate and breast cancer usually recur in the bone, according to a new University of Michigan study.

Now, U-M researchers believe they know why. Prostate cancer cells specifically target and eventually overrun the bone marrow niche, a specialized area for hematopoietic stem cells, which make red and white blood cells, said Russell Taichman, professor at the U-M School of Dentistry and senior author of the study.

Once in the niche, the cancer cells stay dormant and when they become active again years later, that's when tumors recur in the bone. The implication is that this may give us a window as to how dormancy and recurrence take place.

Taichman and a team of researchers looked in the bone marrow and found cancer cells and hematopoietic stem cells next to one another competing for the same place. The finding is important because it demonstrates that the bone marrow niche plays a central role in bone metastasis---cancers that spread into the bone---giving researchers a new potential drug target.

Drugs could be developed to keep the types of cancers that likely recur in the bone from returning, Taichman said. For example, these drugs could either halt or disrupt how the cancer cells enter or behave in the niche, or keep the cancer cells from out-competing the stem cells.

Cancer cells act a lot like stem cells in that they must reproduce, so the U-M research group hypothesized that prostate cancer cells might travel to the niche during metastasis. One of the jobs of the niche is to keep hematopoietic stem cells from proliferating---which may be the case for cancer cells, as well, the researchers found.

So why does cancer recur? Say a person has a tumor and surgeons cut it out or do radiation, but it recurs in the bone marrow five years later, Taichman said. Those cancer cells had been circulating in the body well before the tumor was discovered, and one place those cancer cells hid is the niche.

"So what have the cancer cells been doing during those five years? Now we have a partial answer---they've been sitting in this place whose job it is to keep things from proliferating and growing," Taichman said.

"Our work also provides an explanation as to why current chemotherapies often fail in that once cancer cells enter the niche, most likely they stop proliferating," said Yusuke Shiozawa, lead author of the study. "The problem is that most of the drugs we use to try to treat cancer only work on cells that are proliferating."

Metastases are the most common malignant tumors involving the skeleton, and nearly 70 percent of patients with breast and prostate cancer have bone involvements. Roughly 15 percent to 30 percent of patients with lung, colon, stomach, bladder, uterus, rectum, thyroid or kidney cancer have bone lesions.

Researchers aren't quite sure how the cancer cells out-compete the stem cells in the niche. However, they do know the stem cells were displaced because when cancer cells were in the niche scientists also found evidence of immature blood stem cells in the blood stream, instead of in the marrow where they were supposed to be, Taichman said.

"Eventually the entire blood system is going to collapse," he said. "For example, the patient ultimately becomes anemic, gets infections, and has bleeding problems. We really don't know why people with prostate cancer die. They end up dying from different kinds of complications in part because the marrow is taken over by cancer."

The next step is to find out how the tumor cell gets into the niche and becomes dormant, and exactly what they do to the stem cells when they are there. Researchers also want to know if other types of cancer cells, such as breast cancer, also go to the niche.

The study, "Prostate Cancer Metastases Target the Hematopoietic Stem Cell Niche to Establish Footholds in Marrow," appears online in the Journal of Clinical Investigation.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan
Source:Eurekalert  

Related biology news :

1. Genetic risk factors may tailor prostate cancer screening approaches
2. Prostate cancer spurs new nerves
3. Men with wives, significant others more likely to be screened for prostate cancer
4. New lab evidence suggests preventive effect of herbal supplement in prostate cancer
5. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
6. Freezing prostate cancer does a mans body good
7. New medications show promise in treating drug-resistant prostate cancer
8. New drug shows promise in treating drug-resistant prostate cancer
9. Agent Orange exposure increases veterans risk of aggressive recurrence of prostate cancer
10. 3-D research model tackles prostate cancer spread
11. Gene activity reveals dynamic stroma microenvironment in prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prostate cancer spreads to bones by overtaking the home of blood stem cells
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... offering. ... global voice recognition biometrics market to grow at a CAGR of ... the present scenario and the growth prospects of the global voice ... report considers the revenue generated from the sales of voice recognition ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... Calif. , Feb. 17, 2017  BioGenex, ... to announce development of a novel system for ... collaboration with the University of Rochester (NY, USA) ... ). The new system is able to accurately ... biomarker, HER2 (Human epidermal growth factor receptor-2) in ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will ... event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan ... organization. They provide an opportunity to interact with peers, make new connections and talk ...
(Date:2/16/2017)... , Feb. 16, 2017 ... "Synthetic Biology: Global Markets" report to their ... ... products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, ... synthesis and assembly, genome editing, bioinformatics and specialty media) ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology: